| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Atibuclimab | IC-14 | Phase 2 Clinical | Icos Corporation | Acute Lung Injury; Acutely decompensated congestive heart failure; Amyotrophic Lateral Sclerosis; Arrhythmias, Cardiac; Arrhythmogenic Right Ventricular Dysplasia; Cardiomyopathies; Coronavirus Disease 2019 (COVID-19); Dengue; Lung Diseases; Motor Neuron Disease; Pneumonia; Respiratory Distress Syndrome, Adult; Sepsis; ST Elevation Myocardial Infarction | Details |
| VB-201 | CI-201; VB-201 | Phase 2 Clinical | Notable Labs Ltd | Cardiovascular Diseases; Colitis, Ulcerative; Coronavirus Disease 2019 (COVID-19); HIV Infections; Inflammation; Plaque psoriasis; Psoriasis | Details |
| TCP-25 | TCP-25 | Phase 2 Clinical | Lund University | Blister; Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional; Wounds and Injuries | Details |